Self‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort is a research paper published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0.361. It has been cited 7 times, with 6 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.0490
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 6 citers.
National Institutes of Health
Grant: U01 AG024904
U.S. Department of Defense
Grant: W81XWH‐12‐2‐0012
National Institute on Aging
Grant: P30AG066508
National Institute on Aging
Grant: P30AG021342
National Institute on Aging
Grant: RF1AG081413
National Institute on Aging
Grant: RF1AG068191
NCATS NIH HHS
Grant: UL1 TR001863
NIA NIH HHS
Grant: R01 AG068191
Department of Defense
Grant: W81XWH-12-2-0012
National Institutes of Health
Grant: 1U01AG024904-01
Alzheimers Disease Neuroimaging Initiative
National Institutes of Health
Grant: 1RF1AG081413-01
Integrative analysis for patient-centered outcomes and time-to-event data in Alzheimer's disease
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5P30AG066508-03
Yale Alzheimer Disease Research Center
National Institutes of Health
Grant: 5P30AG021342-13
Information Dissemination Core
National Institutes of Health
Grant: 1RF1AG068191-01A1
Novel integrative imaging genetics analysis for Alzheimer's disease riskand progression
Janssen Alzheimer Immunotherapy Research &Development, LLC.
Merck
Pfizer Inc.
Piramal Imaging
Fujirebio Europe
NeuroRx Research
AbbVie, Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica
BioClinica, Inc.
Novartis Pharmaceuticals Corporation
Servier
The Canadian Institutes of Health Research
Transition Therapeutics
the National Institute of Biomedical Imaging and Bioengineering
F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
Lumosity
Neurotrack Technologies
Pfizer
IXICO Ltd.
Lundbeck
Merck & Co., Inc.
Biogen; Bristol-Myers Squibb Company
CereSpir, Inc.
EuroImmun
Meso Scale Diagnostics, LLC.
Takeda Pharmaceutical Company
Alzheimer's Drug Discovery Foundation
Cogstate; Eisai Inc.
Elan Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development LLC.
the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Eli Lilly and Company
Fujirebio
GE Healthcare
H. Lundbeck A/S
Northern California Institute for Research and Education
Fields of Study
MeSH Terms
Keywords